Both METTL3 and YTHDF1 overexpression resulted in OXA resistance in CRC patients, in which METTL3 induced resistance to OXA through receptor-associated factor 5 (TRAF5)-mediated necroptosis (Lan et al., 2021), and YTHDF1 induced resistance to OXA through the upregulation of glutaminase 1 (GLS1) expression and induced resistance to OXA and DDP (Chen P. et al., 2021; Lin et al., 2024). This evidence concerns the gene METTL3 and colorectal carcinoma.